Abstract
Oncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particular, we examine the KIT, MET and RET receptors that are targeted by genetic alterations in both sporadic and familial human tumours.
Keywords: kinase, tyrosine, oncogene, germline, thyroid, kit, met, ret
Current Medicinal Chemistry
Title: Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics
Volume: 12 Issue: 15
Author(s): Francesca Carlomagno and Massimo Santoro
Affiliation:
Keywords: kinase, tyrosine, oncogene, germline, thyroid, kit, met, ret
Abstract: Oncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particular, we examine the KIT, MET and RET receptors that are targeted by genetic alterations in both sporadic and familial human tumours.
Export Options
About this article
Cite this article as:
Carlomagno Francesca and Santoro Massimo, Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics, Current Medicinal Chemistry 2005; 12 (15) . https://dx.doi.org/10.2174/0929867054367266
DOI https://dx.doi.org/10.2174/0929867054367266 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fireflies in the Coalmine: Luciferase Technologies in Next-Generation Toxicity Testing
Combinatorial Chemistry & High Throughput Screening Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Negative Glucocorticoid Receptor Response Elements and their Role in Glucocorticoid Action
Current Pharmaceutical Design Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Mitochondrial Mechanisms of Metabolic Reprogramming in Proliferating Cells
Current Medicinal Chemistry Lymphoproliferative Disorders and Chemokines
Current Drug Targets The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Action and Function of Vitamin D in Digestive Tract Physiology and Pathology
Current Medicinal Chemistry Inhibition of Sulfotransferases by Xenobiotics
Current Drug Metabolism Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression
Endocrine, Metabolic & Immune Disorders - Drug Targets Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers
Current Cancer Drug Targets The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry Docking-Based Virtual Screening: Recent Developments
Combinatorial Chemistry & High Throughput Screening Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery